Product Description
Mechanisms of Action: ADORA1 Antagonist,ADORA2 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Topical,Inhalant
FDA Designation: None *
Approval Status: Approved
Approved Countries: Austria | Bulgaria | Canada | Chile | China | Colombia | Dominican Republic | Egypt | Hong Kong | India | Ireland | Lebanon | Morocco | New Zealand | Pakistan | Portugal | Russia | Spain | Taiwan | Tunisia | Turkey
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|